Google
SNY Stock Analysis — SANOFI ADR (Healthcare >> Drug Manufacturers - General)
SNY FAQ
What is SNY's P/E ratio?
SANOFI ADR (SNY) currently trades at a P/E ratio of 21.59.
What is SNY's ROE?
SANOFI ADR reports a Return on Equity (ROE) of 5.72%.
What is SNY's dividend yield?
SANOFI ADR offers a dividend yield of 0.00%.
What is SNY's Quality Score?
Our AI rates SNY's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SNY?
Our AI Timing Score for SNY is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SNY belong to?
SANOFI ADR is classified under the Healthcare >> Drug Manufacturers - General sector on the NASDAQ exchange
SNY AI Analysis Summary
Our AI summary for SNY: SANOFI ADR (NASDAQ), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 21.59, ROE of 5.72%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 43.08
Price
0.19
(0.44%)
Day Change
|
|
|---|
SNY, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is ok , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 86 |
| Magic Formula Rank by ROA |
1386
|
| Magic Formula Rank by ROE |
1386
|
| Magic Formula Rank by ROIC |
2139
|
| Price | 43.08 |
| PBV / Sector |
1.48 / 2.68
GOOD
|
| Earning Per Share | 1.66 |
| PE / Sector |
21.59 / 27.65
|
| PEG or PE/Growth / Sector |
5.52 / 0.28
|
| Average 1M Daily Value |
149.88 M
GREAT
|
| Average 1W Daily Value |
196.05 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
52% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
33% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:30 |
| Symbol | SNY |
| Name | SANOFI ADR |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NASDAQ |
| Listed Shares | 2,396.14 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 102,770.34 / 256,404.20 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 46, avenue de la Grande ArmEe, Paris, France, 75017
Phone: 33 1 53 77 40 00
Website: https://www.sanofi.com
Employees: 74,846
Description: Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
